Case 2: Relationship Between LDL and Major Adverse CV Events
Read More
Case 2: Combination of Device and Drug for Patients With Stents
The Role of L-Glutamine in Treating SCD
Mechanism of Action of Hydroxyurea
Managing AD and Treatment Adherence in Patients of Color
Burdens of Atopic Dermatitis in Patients With Skin of Color
Roles and Communication in Treatment in DTC
Management of DTC in Clinical Practice
Expert Perspectives on Management of Rheumatic Diseases: Post ACR Convergence 2020
Take-Home Messages from ACR 2020: Behcet’s Disease
Take-Home Messages from ACR 2020: Psoriatic Arthritis
Progressive Nature and Severity of Rheumatic Diseases
Selecting Therapy to Treat C. Difficile.
C. Difficile: Updates to Clinical Practice Guidelines
C. Difficile Risk Factors and Manifestation
C. Difficile: Clinical Practice Guidelines and Treatment Options
Screening for C. Difficile
Testing for C. Difficile Infections
C. Difficile: A Differential Diagnosis
Recurrent C. Difficile
Case 2: Triple Antiplatelet Therapy in Patients With Stents
Case 1: THEMIS Trial and Subgroup Analysis With Revascularization
Case 1: Choice of Therapy for Peripheral Artery Disease
Case 1: Antithrombotic Regimen in High-Risk Patient
Rationale and Study Design of the VOYAGER PAD Trial
COMPASS Trial: Subgroup Analysis and Implications
Role of NOACs in Venous Thromboembolism and COMPASS Trial
How COVID-19 Has Impacted Patients With SCD
Complications of Sickle Cell Disease
Sickle Cell Disease Prevalence and Pathophysiology